Occult collision tumor of the gastroesophageal junction comprising adenocarcinomas with distinct molecular profiles.
Maryjka B Blaszczyk, Sarag A Boukhar, Zhongren Zhou...
https://pubmed.ncbi.nlm.nih.gov/39805155/Actively Recruiting
Led by Rutgers, The State University of New Jersey · Updated on 2026-04-17
1100
Participants Needed
11
Research Sites
N/A
Total Duration
Researchers are studying targeted genomic analysis of blood and tissue samples from patients with cancer, focusing on rare cancers with poor prognosis or limited treatment options. This observational research aims to identify genetic changes using genomic sequencing to help understand cancer development and to provide clinicians with mutation data that may guide treatment or referral to relevant studies. The study also collects clinical outcomes and tumor genome data for future analysis and cancer model development. The study involves analyzing previously collected tumor tissue samples using next-generation sequencing to detect mutations. Patients may also provide blood samples for analysis of circulating cell-free DNA and circulating tumor cells. These procedures support the identification of actionable mutations that may have available targeted therapies. The research includes correlative laboratory biomarker analysis. Participants are followed after study completion every 3 months for 2 years, then every 6 months for up to 15 years to monitor clinical outcomes and mutation frequencies. Researchers measure the frequency of specific mutations and the rate of actionable mutations in rare or poor prognosis cancers over this period. This long-term follow-up helps correlate genomic findings with patient outcomes and supports future research developments.
CONDITIONS
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
C
Clinical Trials Office
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rutgers, The State University of New Jersey
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants provide previously collected tumor tissue samples and may undergo blood sample collection for genomic analysis.
1 visit (in-person) for blood sample collection; tissue samples are previously collected
Duration - Up to 15 years
Participants are followed up to collect clinical outcomes and monitor genomic data every 3 months for 2 years, then every 6 months for up to 15 years.
Follow-up visits every 3 months for 2 years, then every 6 months for up to 15 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Maryjka B Blaszczyk, Sarag A Boukhar, Zhongren Zhou...
https://pubmed.ncbi.nlm.nih.gov/39805155/Rutgers, The State University of New Jersey
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor